Report finds new approved patented medicines have high treatment costs
The Patented Medicine Prices Review Board (PMPRB) published its seventh edition of its annual Meds Entry Watch Report, which found that the number of new medicines launched in Canada was higher...To view the full article, register now.
Already a subscriber? Click here to view full article